IPO
MCID: INT072
MIFTS: 46

Intestinal Pseudo-Obstruction (IPO) malady

Categories: Rare diseases, Gastrointestinal diseases, Neuronal diseases, Fetal diseases

Aliases & Classifications for Intestinal Pseudo-Obstruction

About this section

Aliases & Descriptions for Intestinal Pseudo-Obstruction:

Name: Intestinal Pseudo-Obstruction 11 48 25 27 50 39 13 68
Hollow Visceral Myopathy 48 68
Paralytic Ileus 25 68
Congenital Idiopathic Intestinal Pseudoobstruction 68
Chronic Idiopathic Intestinal Pseudo-Obstruction 25
Pseudointestinal Obstruction Syndrome 25
Congenital Short Bowel Syndrome 25
 
Pseudo-Obstruction of Intestine 11
Intestinal Pseudoobstruction 48
Intestine Pseudoobstruction 11
Pseudoobstructive Syndrome 25
Enteric Neuropathy 25
Ciip 25
Ipo 25

Classifications:



External Ids:

Disease Ontology11 DOID:3878
MeSH39 D007418
SNOMED-CT62 235825006
NCIt45 C34733

Summaries for Intestinal Pseudo-Obstruction

About this section
NIH Rare Diseases:48 Intestinal pseudo-obstruction is a digestive disorder in which the intestinal walls are unable to contract normally (called hypomotility); the condition resembles a true obstruction, but no actual blockage exists. signs and symptoms may include abdominal pain; vomiting; diarrhea; constipation; malabsorption of nutrients leading to weight loss and/or failure to thrive; and other symptoms. it may be classified as neuropathic (from lack of nerve function) or myopathic (from lack of muscle function), depending on the source of the abnormality. the condition is sometimes inherited (in an x-linked recessive or autosomal dominant manner) and may be caused by mutations in the flna gene; it may also be acquired after certain illnesses. the goal of treatment is to provide relief from symptoms and ensure that nutritional support is adequate. last updated: 4/1/2015

MalaCards based summary: Intestinal Pseudo-Obstruction, also known as hollow visceral myopathy, is related to paralytic ileus and intestinal pseudoobstruction, neuronal, and has symptoms including vomiting An important gene associated with Intestinal Pseudo-Obstruction is TYMP (Thymidine Phosphorylase), and among its related pathways is Smooth Muscle Contraction. Affiliated tissues include smooth muscle, small intestine and colon, and related mouse phenotypes are digestive/alimentary and respiratory system.

Genetics Home Reference:25 Intestinal pseudo-obstruction is a condition characterized by impairment of the muscle contractions that move food through the digestive tract. The condition may arise from abnormalities of the gastrointestinal muscles themselves (myogenic) or from problems with the nerves that control the muscle contractions (neurogenic).

Wikipedia:71 Intestinal pseudo-obstruction is a clinical syndrome caused by severe impairment in the ability of the... more...

Related Diseases for Intestinal Pseudo-Obstruction

About this section

Diseases in the Intestinal Obstruction family:

intestinal pseudo-obstruction

Diseases related to Intestinal Pseudo-Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 121)
idRelated DiseaseScoreTop Affiliating Genes
1paralytic ileus12.5
2intestinal pseudoobstruction, neuronal11.9
3chronic intestinal pseudoobstruction11.8
4visceral myopathy11.5
5chronic atrial and intestinal dysrhythmia11.4
6mitochondrial neurogastrointestinal encephalopathy disease11.3
7congenital short bowel syndrome11.1
8mungan syndrome11.1
9colonic pseudo-obstruction11.1
10autoimmune gastrointestinal dysmotility11.1
11systemic lupus erythematosus10.4
12lupus erythematosus10.4
13myopathy10.3
14ciliary dyskinesia, due to transposition of ciliary microtubules10.2ACTG2, SOX10
15neuropathy10.2
16peritonitis10.2
17amyloidosis10.2
18hemangioma, capillary infantile10.1ACTG2, MYH11
19deafness, mitochondrial, modifier of10.1EDNRB, SOX10
20wdha syndrome10.1EDNRB, SOX10
21thymoma10.1
22neuronitis10.1
23cervical adenofibroma10.1EDNRB, SOX10
24syphilitic encephalitis10.1FLNA, MT-TL1
25kawasaki disease10.0
26myasthenia gravis10.0
27waardenburg syndrome, type 4a10.0EDNRB, RET
28pancreatitis9.9
29myotonic dystrophy9.9
30polymyositis9.9
31encephalopathy9.9
32patellofemoral pain syndrome9.9FLNA, RET
33hypoparathyroidism-intellectual disability-dysmorphism syndrome9.9RET, SYP
34early-onset parkinson disease9.9RET, SYP
35herpetic whitlow9.9FLNA, RET
36hirschsprung disease 19.9EDNRB, RET
37cowden syndrome 39.9RET, SYP
38pheochromocytoma9.9
39crohn's disease9.9
40small cell carcinoma9.9
41gastroparesis9.9
42pneumatosis cystoides intestinalis9.9
43diarrhea9.9
44patent ductus arteriosus9.9
45constipation9.9
46autonomic dysfunction9.9
47ichthyosis lamellar 29.8FLNA, L1CAM, SYP
48ceroid lipofuscinosis, neuronal, 59.8EDNRB, RET, SOX10
49skin pilomatrix carcinoma9.8EDNRB, RET, SOX10
50urinary tract papillary transitional cell benign neoplasm9.8RET, SYP

Graphical network of the top 20 diseases related to Intestinal Pseudo-Obstruction:



Diseases related to intestinal pseudo-obstruction

Symptoms & Phenotypes for Intestinal Pseudo-Obstruction

About this section

UMLS symptoms related to Intestinal Pseudo-Obstruction:


vomiting

MGI Mouse Phenotypes related to Intestinal Pseudo-Obstruction according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.7EDNRB, FLNA, MYH11, RET, SOX10
2MP:00053887.9EDNRB, FLNA, MYH11, RET, SOX10
3MP:00053847.8EDNRB, FLNA, L1CAM, MYH11, RET, SOX10
4MP:00036317.5EDNRB, FLNA, L1CAM, RET, SOX10, SYP

Drugs & Therapeutics for Intestinal Pseudo-Obstruction

About this section

Drugs for Intestinal Pseudo-Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1ColaNutraceuticalPhase 3, Phase 21946
2
FludarabineapprovedPhase 2115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
3
rituximabapprovedPhase 21692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
4
ThiotepaapprovedPhase 222652-24-45453
Synonyms:
 
Thioplex
5
Busulfanapproved, investigationalPhase 254555-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
6
Celecoxibapproved, investigationalPhase 2444169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
7
alemtuzumabapproved, investigationalPhase 2310216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
8
Acetylcysteineapproved, investigationalPhase 2330616-91-112035
Synonyms:
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
 
L-Acetylcysteine
L-acetylcysteine
L-α-acetamido-β-mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
9
Vitamin Eapproved, nutraceutical, vet_approvedPhase 241459-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
10Pharmaceutical SolutionsPhase 28192
11Thioctic AcidPhase 2118
12TocotrienolsPhase 2410
13VitaminsPhase 25282
14TocopherolsPhase 2414
15N-monoacetylcystinePhase 2330
16Antilymphocyte SerumPhase 2408
17Antimetabolites, AntineoplasticPhase 27361
18AntimetabolitesPhase 212054
19Alkylating AgentsPhase 24827
20Immunosuppressive AgentsPhase 213086
21Antineoplastic Agents, AlkylatingPhase 24603
22Alpha-lipoic AcidNutraceuticalPhase 2118
23TocopherolNutraceuticalPhase 2414
24TocotrienolNutraceuticalPhase 2410

Interventional clinical trials:

(show all 15)
idNameStatusNCT IDPhase
1The Effects of Gum Chewing on Bowel Function Recovery Following Cesarean SectionCompletedNCT01131416Phase 2, Phase 3
2Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or SurgeryCompletedNCT00140868Phase 3
3Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)CompletedNCT01553591Phase 3
4Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)CompletedNCT01553747Phase 3
5Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian CancerWithdrawnNCT01389986Phase 2, Phase 3
6Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After PancreaticoduodenectomyUnknown statusNCT01607307Phase 2
7Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)CompletedNCT00793247Phase 2
8Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With DiarrheaCompletedNCT01130272Phase 2
9MT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisRecruitingNCT02171104Phase 2
10Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)TerminatedNCT00065234Phase 2
11Efficacy and Safety of Fecal Microbiota Transplantation for Chronic Intestinal Pseudo-obstructionRecruitingNCT02731183Phase 1
12Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-upCompletedNCT00213460
13Effects of Laser Acupuncture Therapy on Paralytic IleusRecruitingNCT03041675
14Measurement of Body Composition by Air Displacement Plethysmography in Pediatric Intestinal Failure PatientsRecruitingNCT02561819
15Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in InfantsTerminatedNCT01062815

Search NIH Clinical Center for Intestinal Pseudo-Obstruction


Cochrane evidence based reviews: intestinal pseudo-obstruction

Genetic Tests for Intestinal Pseudo-Obstruction

About this section

Genetic tests related to Intestinal Pseudo-Obstruction:

id Genetic test Affiliating Genes
1 Intestinal Pseudo-Obstruction27

Anatomical Context for Intestinal Pseudo-Obstruction

About this section

MalaCards organs/tissues related to Intestinal Pseudo-Obstruction:

36
Smooth muscle, Small intestine, Colon, Lung, Liver, Lymph node

Publications for Intestinal Pseudo-Obstruction

About this section

Articles related to Intestinal Pseudo-Obstruction:

(show top 50)    (show all 453)
idTitleAuthorsYear
1
Chronic intestinal pseudo-obstruction in children and adults: diagnosis and therapeutic options. (27683196)
2017
2
Chronic intestinal pseudo-obstruction in a child harboring a founder Hirschsprung RET mutation. (27273837)
2016
3
Utility of Octreotide in Advancing Enteral Feeds in Children with Chronic Intestinal Pseudo-Obstruction. (27520652)
2016
4
Comparative quantitative assessment of global small bowel motility using magnetic resonance imaging in chronic intestinal pseudo-obstruction and healthy controls. (26661570)
2016
5
Chronic Intestinal Pseudo-Obstruction: Clinical and Manometric Characteristics in the Chilean Population. (27669829)
2016
6
Intestinal Leiomyositis: A Cause of Chronic Intestinal Pseudo-Obstruction in 6 Dogs. (26608226)
2016
7
Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. (26615031)
2016
8
Clinical Features, Morbidity, and Risk Factors of Intestinal Pseudo-obstruction in Systemic Lupus Erythematosus: A Retrospective Case-control Study. (26773109)
2016
9
Chronic Intestinal Pseudo-Obstruction. (27305875)
2016
10
Variants of the ACTG2 gene correlate with degree of severity and presence of megacystis in chronic intestinal pseudo-obstruction. (26813947)
2016
11
Surgical abdomen with intestinal pseudo-obstruction as presenting feature of atypical Kawasaki disease. (27654849)
2016
12
Myofibrillar Myopathy Presenting as Neonatal Intestinal Pseudo-Obstruction: An Extremely Rare Entity. (26828629)
2016
13
Intestinal pseudo-obstruction in mitochondrial diseases. (27804144)
2016
14
Serial Frozen Fecal Microbiota Transplantation in the Treatment of Chronic Intestinal Pseudo-obstruction: A Preliminary Study. (27840368)
2016
15
Smooth-Muscle Myopathy in Systemic Lupus Erythematosus Presenting With Intestinal Pseudo-Obstruction. (27694873)
2016
16
Mitochondrial respiratory chain complex IV deficiency complicated with chronic intestinal pseudo-obstruction in a neonate. (27264907)
2016
17
Ellis-van Creveld syndrome associated with chronic intestinal pseudo-obstruction. (26818569)
2016
18
Clinical importance of cine-MRI assessment of small bowel motility in patients with chronic intestinal pseudo-obstruction: a retrospective study of 33 patients. (27549243)
2016
19
Chronic intestinal pseudo-obstruction: An unusual presentation. (27852553)
2016
20
Acute lupus pneumonitis followed by intestinal pseudo-obstruction in systemic lupus erythematosus: A case report. (27347044)
2016
21
Two Cases of Chronic Intestinal Pseudo-obstruction: A Comparison of Staining Characteristics of Enteric Visceral Myopathy With Hirschsprung Disease. (26808129)
2016
22
Percutaneous endoscopic cecostomy (introducer method) in chronic intestinal pseudo-obstruction - report of two cases and literature review. (26493622)
2015
23
Clinical analysis of 61 systemic lupus erythematosus patients with intestinal pseudo-obstruction and/or ureterohydronephrosis: a retrospective observational study. (25634172)
2015
24
Kawasaki's disease: an often overlooked cause of intestinal pseudo-obstruction in children. (26386569)
2015
25
Mutations in RAD21 Disrupt Regulation of APOB in Patients With Chronic Intestinal Pseudo-Obstruction. (25575569)
2015
26
Abnormal layering of muscularis propria as a cause of chronic intestinal pseudo-obstruction: A case report and literature review. (26078585)
2015
27
A review of 42 cases of intestinal pseudo-obstruction in patients with systemic lupus erythematosus based on case reports. (26429329)
2015
28
A case report of chronic intestinal pseudo-obstruction with autoimmune autonomic ganglionopathy suspected from seropositive results for anti-ganglionic acetylcholine receptor antibody. (25744921)
2015
29
Predictors of intestinal pseudo-obstruction in systemic lupus erythematosus complicated by digestive manifestations: data from a Southern China lupus cohort. (26405024)
2015
30
OP-8 SOCIAL CONCERNS IN CHILDREN BEING INVESTIGATED FOR CHRONIC INTESTINAL PSEUDO-OBSTRUCTION. (26439549)
2015
31
Intestinal pseudo-obstruction following oral baclofen: An unusual complication. (26312004)
2015
32
Intestinal Pseudo-Obstruction as an Initial Manifestation of Systemic Lupus Erythematosus. (26131004)
2015
33
Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge. (25170234)
2014
34
Familial visceral myopathy diagnosed by exome sequencing of a patient with chronic intestinal pseudo-obstruction. (24777424)
2014
35
Intestinal pseudo-obstruction as a presenting symptom of Guillain-BarrAc syndrome. (25015168)
2014
36
Urinary tract involvement in systemic lupus erythematosus: Coexistence with lupus mesenteric vasculitis or intestinal pseudo-obstruction? (24953799)
2014
37
Acute refractory intestinal pseudo-obstruction in MELAS: efficacy of prucalopride. (24789860)
2014
38
Chronic intestinal pseudo-obstruction: systematic histopathological approach can clinch vital clues. (24663670)
2014
39
Intestinal pseudo-obstruction as an unusual gastrointestinal presentation in pediatric human immunodeficiency virus infection. (24453397)
2014
40
Intestinal pseudo-obstruction in systemic lupus erythematosus: a case report and review of the literature. (25546663)
2014
41
Pediatric chronic intestinal pseudo-obstruction is a rare, serious, and intractable disease: a report of a nationwide survey in Japan. (25487487)
2014
42
Advancement in the clinical management of intestinal pseudo-obstruction. (25020006)
2014
43
Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction. (25128517)
2014
44
Iodine Deficiency in a Parenteral Nutrition-Dependent Adolescent With Intestinal Pseudo-obstruction. (25261415)
2014
45
The great masquerader of malignancy: chronic intestinal pseudo-obstruction. (25635225)
2014
46
Intestinal pseudo-obstruction due to small bowel I+-actin deficiency in a child with Ehlers-Danlos syndrome. (23963838)
2013
47
Isolated intestinal transplant for chronic intestinal pseudo-obstruction in adults: long-term outcome. (24182815)
2013
48
Clinical recovery of chronic intestinal pseudo-obstruction with cisapride in a complex pediatric patient. (22964344)
2013
49
Intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus. (23104391)
2013
50
Transgastric long tube placement following percutaneous endoscopic gastrostomy for severe chronic intestinal pseudo-obstruction related to systemic sclerosis. (24252025)
2013

Variations for Intestinal Pseudo-Obstruction

About this section

Expression for genes affiliated with Intestinal Pseudo-Obstruction

About this section
Search GEO for disease gene expression data for Intestinal Pseudo-Obstruction.

Pathways for genes affiliated with Intestinal Pseudo-Obstruction

About this section

Pathways related to Intestinal Pseudo-Obstruction according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.8ACTG2, MYH11

GO Terms for genes affiliated with Intestinal Pseudo-Obstruction

About this section

Cellular components related to Intestinal Pseudo-Obstruction according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1myosin filamentGO:00329829.8ACTG2, MYH11

Biological processes related to Intestinal Pseudo-Obstruction according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1melanocyte differentiationGO:003031810.0EDNRB, SOX10
2peripheral nervous system developmentGO:00074229.9EDNRB, SOX10
3posterior midgut developmentGO:00074979.5EDNRB, RET
4enteric nervous system developmentGO:00484849.2EDNRB, RET, SOX10
5response to painGO:00482659.1EDNRB, RET
6neural crest cell migrationGO:00017559.1EDNRB, RET, SOX10

Sources for Intestinal Pseudo-Obstruction

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet